Federal contract award
75F40123C00204
IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $375.5K |
| Current contract value | $375.5K |
| Potential contract value / ceiling | $507.3K |
| Start date | Sep 22, 2023 |
| Current end date | Sep 29, 2026 |
| Potential end date | Sep 29, 2027 |
| Latest award activity | Dec 9, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 9, 2025 | P00005 | $0 | IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION |
| Aug 7, 2025 | P00004 | $131.4K | IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION |
| Nov 18, 2024 | P00003 | $0 | IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION |
| Jul 29, 2024 | P00002 | $125.0K | IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION |
| Jan 29, 2024 | P00001 | $0 | IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION |
| Sep 22, 2023 | 0 | $119.0K | IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION |
Estimated positioning window
Nov 1, 2026 – Mar 29, 2027
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2027-09-29 (332 days from calculation)
- +35 points
- 46 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2025-12-09
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.